Home › Research › Drug development
GLP-1 receptor agonists reduce dementia and Alzheimer disease risk in diabetic patients with CKD
Wen-Teng Lee, Jing Tong WANG, Ming‐Hsien Tsai, Yu‐Wei Fang. Nephrology Dialysis Transplantation, 2026-02-14
Topic: Brain proteins, microglia and lab models
Plain-language summary
GLP-1RA use was associated with a significantly lower risk of dementia [hazard ratio (HR) 0.80, 95% confidence interval (CI) 0.71-0.91, P = .001] and Alzheimer's disease (HR 0.76, 95% CI 0.59-0.98, P = .033) compared with DPP4i use. However, no significant differences were observed in vascular dementia, frontotemporal dementia, Parkinson's disease, extrapyramidal and movement disorders, or dementia with Lewy bodies. GLP-1RA therapy may reduce the risk of dementia and Alzheimer's disease in patients with CKD stage 3 or later, offering potential neuroprotective benefits beyond glycemic control. Research is needed to confirm these findings and optimize treatment strategies for this vulnerable population.
What this study adds
Evidence grade: Moderate
This is a follow-up (cohort) study. In this observational study, people with diabetes and chronic kidney disease who took GLP-1 receptor agonists had a lower risk of being diagnosed with dementia and Alzheimer's disease than those who took DPP4 inhibitors. Reported effect size: HR 0.76.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Lee, W.-T., Jing Tong, W. A. N. G., Tsai, M., & Fang, Y. (2026). GLP-1 receptor agonists reduce dementia and Alzheimer disease risk in diabetic patients with CKD. Nephrology Dialysis Transplantation. https://doi.org/10.1093/ndt/gfag032
Vancouver
Lee W.-T, Jing Tong WANG, Tsai M, Fang Y. GLP-1 receptor agonists reduce dementia and Alzheimer disease risk in diabetic patients with CKD. Nephrology Dialysis Transplantation. 2026. doi:10.1093/ndt/gfag032. PMID: 41697144.
BibTeX
@article{lee2026-41697144,
author = {Lee, Wen-Teng and Jing Tong, W. A. N. G. and Tsai, Ming‐Hsien and Fang, Yu‐Wei},
title = {{GLP-1 receptor agonists reduce dementia and Alzheimer disease risk in diabetic patients with CKD}},
journal = {Nephrology Dialysis Transplantation},
year = {2026},
doi = {10.1093/ndt/gfag032},
pmid = {41697144},
url = {https://doi.org/10.1093/ndt/gfag032}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- GLP-1RA use was associated with a significantly lower risk of dementia [hazard ratio (HR) 0.80, 95% confidence interval (CI) 0.71-0.91, P = .001] and Alzheimer's disease (HR 0.76, 95% CI 0.59-0.98, P = .033) compared with DPP4i use.
- However, no significant differences were observed in vascular dementia, frontotemporal dementia, Parkinson's disease, extrapyramidal and movement disorders, or dementia with Lewy bodies.
- GLP-1RA therapy may reduce the risk of dementia and Alzheimer's disease in patients with CKD stage 3 or later, offering potential neuroprotective benefits beyond glycemic control.
- Research is needed to confirm these findings and optimize treatment strategies for this vulnerable population.
Why it matters
In this observational study, people with diabetes and chronic kidney disease who took GLP-1 receptor agonists had a lower risk of being diagnosed with dementia and Alzheimer's disease than those who took DPP4 inhibitors. The study authors say more research is needed to confirm these findings, and no differences were seen for several other brain conditions.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Study designcohort study
- Effect sizeHR 0.76
- Evidence strengthModerate
How this study scored 46/100
Published in a peer-reviewed journal, and it is a cohort study following people over time. Scored zero for sample size, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Nephrology Dialysis Transplantation) |
| Journal's citation record | 2 / 4 | Nephrology Dialysis Transplantation: journal h-index 233 (OpenAlex, 2026-10-29) |
| Study design | 7 / 12 | A cohort study following people over time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 3 / 3 | Effect reported with a statistic (interval, p-value, ratio or similar) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 1 / 7 | Cited 2 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 1.0 citations a year over 2 year(s) since 2026 |
| Impact for its field and year | 4 / 6 | Cited 9.4× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 2 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 1 / 4 | Last-listed author Yu‐Wei Fang: h-index 12 (OpenAlex, whole career) |
| Institution's track record | 0 / 3 | Fu Jen Catholic University: institution h-index 213 (OpenAlex) |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 41697144) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 46 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Drug development from nearby years
Also tagged “trial”
783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.